The use of health technology assessment (HTA) to inform policy-making is established in most developed countries. Compared to licensing agencies, HTA agencies have different interests and, therefore, different evidence requirements. Criteria for coverage or reimbursement decisions on pharmaceutical compounds vary; however, it is common to include, as part of the HTA, a comparative effectiveness...

Arterial hypertensions (HTA) of endocrine origin are a rare cause of hypertension; HTA overall prevalence don't exceed 4% of hypertensive patients. Research interest in endocrine HTA is due to the severity of some life-threatening, potentially curable and reversible forms of HTA. The aim of our study was to determine the clinical, paraclinical, etiological and therapeutic profile of secondary H...

Recommendation by the High Level Pharmaceutical Forum (2008): national authorities and companies to be engaged in early dialogues with the aim of improving the generation of appropriate data for products in development (Recommendation 6). First Early Dialogue Initiatives: ‘single HTA’ advice (since 2009) and parallel regulatory HTA advice organized by the EMA with a limited number of HTA bodies...

OBJECTIVES Health technology assessment (HTA) has to innovate to best support changing health system environments and to help provide access to valuable innovation under fiscal constraint. METHODS Issues associated with changing HTA paradigms were identified through scoping and explored through deliberation at a meeting of industry and HTA leaders. RESULTS Five broad areas of change (engage...

OBJECTIVES This study is to review health technology assessment (HTA) development in China during the past two decades, and to facilitate further development of HTA and its integration into policy making. METHODS The study depends very much on the extensive experiences of the authors in involvement of HTA in China. In addition, literature review and Web site searching have been used to trace ...

BACKGROUND Public and patient involvement in the different stages of the health technology assessment (HTA) process is increasingly encouraged. The selection of topics for assessment, which includes identifying and prioritizing HTA questions, is a constant challenge for HTA agencies because the number of technologies requiring an assessment exceeds the resources available. Public and patient in...

OBJECTIVE Middle-income countries are often referred to as developing or emerging economies and face multiple challenges of severe financial stresses in their health care sectors, and high disease burden. The objective of this study is to provide an overview of how health technology assessment (HTA) is used and organized in selected middle-income countries and its role in the process of pharmac...

BACKGROUND Whether type 2 diabetes mellitus (DM) in the absence of hypertension (HTA) and coronary artery disease (CAD) affects left ventricular (LV) phenotype and function among asymptomatic DM patients that can be easily discovered in everyday practice, what is the clinical risk profile for diabetic cardiomyopathy and how HTA and CAD modulate LV structure and function above diabetic cardiomyo...

OBJECTIVES The current and past situation of health technology assessment (HTA) in Catalonia is presented in this study. METHODS The approach used here is a historical review of facts and landmarks. RESULTS Spain has undergone radical change in many aspects, but the changes in healthcare provision have been major indeed. Catalonia has had the ability to benefit from these changes and has be...

I. The workshop begins with an introduction by T. Larsen of key concepts and basic typology of health technology assessment (HTA), which will be illustrated by analytical elements from integrated home care. II. Questions for debate as presented and moderated by the workshop chair [Silvina Santana, University of Aveiro, Portugal] shall focus: 1) In which cases are HTA relevant? It is suggested t...